Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year	Current	2023	2022	2021	2020	2019
Market Capitalization	228	280	585	447	1,823	274
Market Cap Growth	22.40%	-52.15%	30.71%	-75.46%	564.32%	190.08%
Enterprise Value	78	104	340	308	1,584	182
PE Ratio	-	-1.63	-2.86	-2.63	-20.70	-9.73
PS Ratio	5.94	7.59	22.00	10402.13	2201.35	6.51
PB Ratio	8.13	7.58	6.35	3.67	7.99	3.50
P/FCF Ratio	-3.12	-1.64	-11.34	-3.18	-24.25	-4.01
P/OCF Ratio	-3.15	-1.66	-11.84	-3.20	-24.40	-4.05
EV/Sales Ratio	2.02	2.83	12.80	7151.64	1913.28	4.33
EV/EBITDA Ratio	-3.13	-0.64	-1.73	-1.85	-18.28	-6.82
EV/EBIT Ratio	-3.01	-0.62	-1.69	-1.82	-18.07	-6.52
EV/FCF Ratio	-2.26	-0.61	-6.60	-2.19	-21.08	-2.67
Debt / Equity Ratio	1.18	0.91	0.39	0.31	0.07	0.10
Debt / EBITDA Ratio	-0.26	-0.21	-0.18	-0.23	-0.19	-0.29
Debt / FCF Ratio	-0.19	-0.20	-0.70	-0.27	-0.22	-0.11
Quick Ratio	3.43	3.29	3.39	3.74	8.50	4.15
Current Ratio	3.51	3.36	3.49	3.98	8.62	4.21
Asset Turnover	0.15	0.13	0.09	0	0.00	0.33
Interest Coverage	-31.95	-41.15	-60.36	-133.22	-244.25	-119.55
Return on Equity (ROE)	-260.70%	-282.40%	-178.80%	-101.40%	-43.10%	-27.90%
Return on Assets (ROA)	-54.00%	-62.60%	-70.40%	-73.50%	-36.30%	-21.80%
Return on Capital (ROIC)	-233.98%	-254.72%	-158.75%	-105.59%	-36.01%	-35.08%
Earnings Yield	-59.23%	-61.37%	-34.93%	-38.02%	-4.83%	-10.28%
FCF Yield	-76.42%	-61.14%	-8.82%	-31.44%	-4.12%	-24.91%
Buyback Yield / Dilution	-12.94%	-23.98%	-32.69%	-14.79%	-41.37%	-88.83%
Total Shareholder Return	-12.94%	-23.98%	-32.69%	-14.79%	-41.37%	-88.83%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).